Clinical trial
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (Relapsing-remitting Multiple Sclerosis and Active Secondary Progressive Multiple Sclerosis)
NCT04940065 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (Relapsing-remitting Multiple Sclerosis and Active Secondary Progressive Multiple Sclerosis)
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Observational
- Overall status
- Completed
- Start date
- June 30, 2021
- Completion date
- December 12, 2024
- Enrollment
- 367 (actual)
- Sites
- 103
Conditions
As the registry lists them; a condition with its own page is linked.
active secondary progressive multiple sclerosis, relapsing-remitting multiple sclerosis